VEA - ETF AI Analysis
Top Page
Vanguard FTSE Developed Markets ETF (VEA)
VEA, the Vanguard FTSE Developed Markets ETF, earns a solid overall rating thanks to strong core holdings like HSBC, Novartis, and AstraZeneca, which show healthy financial performance, positive earnings, and good long-term prospects. Pharmaceutical leaders such as Roche and energy giant Shell also add stability, though their valuation and growth challenges, along with some overbought signals in certain financial stocks, introduce risk. The main risk factor is the fund’s reliance on large developed-market financial and healthcare companies, which can make performance sensitive to sector-specific downturns.
VEA vs. SPDR S&P 500 ETF (SPY)
- AUM
- 231.73B
- Region
- Developed Markets
- Expense Ratio
- 0.03%
- Beta
- 0.78
- Issuer
- Vanguard
- Inception Date
- Jul 20, 2007
- Dividend Yield
- 2.45%
- Asset Class
- Equity
- Index Tracked
- FTSE Developed ex US All Cap Net Tax (US RIC) Index
VEA Summary
Vanguard FTSE Developed Markets ETF (VEA) is an international stock fund that follows the FTSE Developed All Cap ex US Index. It invests in companies from developed countries outside the United States, including Japan, the UK, Europe, and Australia. The fund holds many well-known global businesses such as Samsung Electronics and HSBC, across sectors like finance, technology, and healthcare. Someone might invest in VEA to diversify beyond the U.S. market and tap into long-term growth in established economies. A key risk is that its value can go up and down with global stock markets and foreign currency movements.
How much will it cost me?
This ETF has an expense ratio of 0.03%, which means you’ll pay about $0.30 per year for every $1,000 invested. That’s much lower than the average ETF because it’s a passively managed fund that simply tracks an index instead of paying managers to pick individual stocks.
What would affect this ETF?
This ETF focuses on developed markets outside the U.S., so it can benefit if economies in Europe and Asia grow steadily, interest rates eventually ease, and global demand supports its major technology, financial, and health care holdings like Samsung, ASML, HSBC, and Roche. On the downside, higher interest rates, slower growth or recessions in these regions, banking or energy sector stress, and unfavorable local regulations or currency swings could weigh on the fund’s performance.
VEA Top 10 Holdings
VEA is leaning heavily on a trio of rising Asian and European heavyweights: Samsung and SK hynix give the fund a clear semiconductor tilt, while ASML adds more chip-fueled momentum despite some mixed recent trading. On the financial side, HSBC and Mitsubishi UFJ are steady engines, with Mitsubishi UFJ in particular helping lift returns, while Royal Bank of Canada has been more of a quiet contributor. Nestlé, however, has been losing steam, slightly dragging on performance. Overall, the ETF offers broad, developed-market exposure outside the U.S., with notable strength in chips and global banks.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 KR:005930 | Samsung Electronics | 2.82% | $8.88B | KRW 1432.08T | 116.14% | ―― |
 KR:000660 | SK hynix Inc. | 2.30% | $7.25B | KRW 1033.53T | 149.65% | ―― |
 NL:ASML | ASML Holding NV | 2.14% | $6.75B | EUR 539.67B | 50.70% | 76Outperform |
 GB:HSBA | HSBC Holdings | 1.05% | $3.31B | GBP 218.81B | 19.37% | 80Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 GB:SHEL | Shell (UK) | 0.86% | $2.70B | GBP 229.30B | 40.01% | 73Outperform |
 RY | Royal Bank Of Canada | ― | ― | ― | ― | 75Outperform |
 CH:NOVN | Novartis AG | 0.82% | $2.60B | CHF 244.89B | 35.30% | 80Outperform |
 JP:8306 | Mitsubishi UFJ Financial Group | 0.78% | $2.47B | JPY 38.80T | 48.45% | 76Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
VEA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VEA, the sentiment is Negative. The current price of 69.44 is below the 20-day moving average (MA) of 69.91, below the 50-day MA of 71.25, and above the 200-day MA of 69.13, indicating a neutral trend. The MACD of -0.37 indicates Negative momentum. The RSI at 43.33 is Neutral, neither overbought nor oversold. The STOCH value of 77.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VEA.
VEA Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| VEA | $69.44 | $73.00(5.13% Upside) | $231.73B | 0.03% | 58Neutral |
 SCHF | $26.98 | $33.93(25.75% Upside) | $68.26B | 0.03% | 61Neutral |
 SPDW | $49.35 | $60.34(22.26% Upside) | $41.36B | 0.03% | 60Neutral |
 IDEV | $89.21 | $107.66(20.68% Upside) | $34.13B | 0.04% | 66Neutral |
 AVDE | $89.11 | $109.55(22.93% Upside) | $19.65B | 0.23% | 65Neutral |
 DFAI | $41.39 | $49.77(20.25% Upside) | $18.27B | 0.18% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VEA | Vanguard FTSE Developed Markets ETF | 69.44 | 9.89 | 16.61% | |
| SCHF | Schwab International Equity ETF | 26.98 | 3.95 | 17.17% | |
| SPDW | SPDR Portfolio Developed World ex-US ETF | 49.35 | 7.09 | 16.78% | |
| IDEV | iShares Core MSCI International Developed Markets ETF | 89.21 | 11.12 | 14.24% | |
| AVDE | Avantis International Equity ETF | 89.11 | 11.97 | 15.51% | |
| DFAI | Dimensional International Core Equity Market ETF | 41.39 | 5.67 | 15.88% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.